L7RN6 Inhibitors
L7RN6 inhibitors encompass a variety of compounds that influence pathways or cellular processes to reduce the activity of L7RN6 indirectly. These inhibitors work by interfering with the post-translational modifications, signaling cascades, or degradation processes that L7RN6 may rely on for its function. Compounds such as staurosporine and okadaic acid affect the phosphorylation state of proteins. Staurosporine acts as a kinase inhibitor, potentially preventing the phosphorylation necessary for L7RN6 activation, while okadaic acid inhibits phosphatases, potentially keeping L7RN6 in an inactive phosphorylated state.
Staurosporine is a well-known kinase inhibitor that could potentially block the phosphorylation events necessary for the activation of L7RN6. By inhibiting these kinases, the activation of L7RN6 could be impaired, thereby reducing its activity. On the other hand, okadaic acid operates by inhibiting phosphatases, which could result in L7RN6 remaining in an inactive phosphorylated state if its activity is contingent upon dephosphorylation. Other compounds, such as LY294002 and wortmannin, are inhibitors of the PI3K enzyme, which is a key component of the PI3K/AKT/mTOR signaling pathway. This pathway is instrumental in controlling various cellular processes including protein synthesis and degradation. Inhibition of PI3K could lead to a decrease in the stability or activity of L7RN6, assuming that L7RN6 is regulated by this pathway. Rapamycin specifically targets mTOR, another key protein in this pathway, and its inhibition could lead to reduced synthesis of L7RN6, thereby affecting its cellular levels and function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Hsp90 inhibitor that binds to the ATP binding site of Hsp90, consequently inhibiting its chaperone activity. L7RN6 is a client protein of Hsp90, and its proper folding and function depend on Hsp90's activity. Inhibition of Hsp90 by geldanamycin would lead to the destabilization and degradation of L7RN6. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
A derivative of geldanamycin and also an Hsp90 inhibitor, 17-AAG binds to the N-terminal ATP-binding site of Hsp90, thus preventing the proper folding of client proteins. As L7RN6 relies on Hsp90 for its stability, 17-AAG would induce its degradation. | ||||||
Radicicol | 12772-57-5 | sc-200620 sc-200620A | 1 mg 5 mg | $92.00 $333.00 | 13 | |
Another Hsp90 inhibitor that binds competitively to the ATP binding domain of Hsp90, leading to the destabilization of its client proteins, including L7RN6, resulting in reduced activity or degradation of L7RN6. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
A steroidal lactone that disrupts Hsp90 chaperone activity by binding to its C-terminal domain. Withaferin A's binding impairs the maturation of client proteins such as L7RN6, leading to their functional inhibition. | ||||||
Celastrol, Celastrus scandens | 34157-83-0 | sc-202534 | 10 mg | $158.00 | 6 | |
A triterpene that induces heat shock response by increasing Hsp expression. While this can be protective, it also competitively inhibits Hsp90, leading to the potential degradation of dependent client proteins like L7RN6. | ||||||
Novobiocin | 303-81-1 | sc-362034 sc-362034A | 5 mg 25 mg | $128.00 $380.00 | ||
An antibiotic that also acts as an Hsp90 C-terminal inhibitor, disrupting the chaperone cycle. This action can lead to the destabilization of L7RN6, as it interferes with its Hsp90-dependent maturation process. | ||||||
Ganetespib | 888216-25-9 | sc-364496 sc-364496A | 10 mg 250 mg | $273.00 $1040.00 | ||
A small molecule Hsp90 inhibitor that binds to the N-terminal domain of Hsp90, preventing the proper folding of L7RN6, which is presumed to be an Hsp90 client protein, thus leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can downregulate protein synthesis and indirectly lead to the decreased stability of proteins that have a rapid turnover, which could include L7RN6 if it has such properties. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that can reduce Akt signaling, which is important for the regulation of protein synthesis and survival. Inhibition of this pathway can indirectly destabilize proteins like L7RN6 that may require active PI3K/Akt signaling for stability. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Similar to LY294002, wortmannin is a PI3K inhibitor that by reducing Akt signaling could indirectly affect the stability of proteins such as L7RN6 that are dependent on this pathway for their regulation. | ||||||